DataMEDS AI, Inc. MEDS
1.80 USD -0.03 (-1.64%)
At closeNov 4, 2026, 8:27 AM EST
1.78 -0.02 -1.11%
Pre-market · Nov 4, 8:27 AM ET
1.62 Day range 1.83
0.823 52-week range 35.50
- YTD
- -91.00%
- 1 year
- -94.36%
- Market cap
- 9.33M
- Revenue (ttm)
- 7.45M
- Profit margin
- 56.68%
- EPS (ttm)
- -46.68
- Shares out
- 1.75M
- Forward P/E
- -16.87
- YTD return
- -91.00%
- 1-year return
- -94.36%
- Volume
- 185.49K
- Avg volume
- 6.53M
- Open
- 1.83
- Previous close
- 1.83
- Day's range
- 1.62 – 1.83
- 52-week range
- 0.823 – 35.50
- Analysts
- Buy
- Earnings date
- Aug 9, 2024
6M -3.40 (-65.38%)
Key statistics
- Enterprise value
- 3.24M
- PEG ratio
- 0.00
- Price / sales
- 1.78
- Price / book
- 0.91
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -94.90%
- Free cash flow
- 0
- Total cash
- 7.72M
- Total debt
- 193.60K
- Return on equity
- 0.00%
- Short % of float
- 1.13%
- 50-day average
- 7.54
- 200-day average
- 9.04
Analyst view
Consensus: buy
Buy
Price target (mean) —
Ratings (-1m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate 0.00.
Financials — quick view
MEDS Revenue — quarterly 1.78M
MEDS Net income — quarterly -18.36M
MEDS EPS — quarterly -7.13
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jun 26, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Jan 16, 2024 | Sep 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -0.30 | — | — | — |
| Mar 27, 2023 | Dec 1, 2022 | -0.90 | — | — | — |
About DataMEDS AI, Inc.
TRxADE HEALTH, Inc. operates as health services IT company. It offers an online web-based buying and selling platform for licensed pharmaceutical wholesalers to sell brand, generic, and non-drug products and services to government organizations, hospitals, clinics and independent pharmacies. TRxADE HEALTH, Inc. is headquartered in Tampa, Florida.
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Country
- United States
- Website
- trxadehealth.com
News
DataMeds AI Terminates Second Amended LOI With Datavault AI And Partners Due To Market Conditions; No Shares To Be Issued Under LOI, Existing REBOOT And Datavault Agreements Remain In Effect; Co Does Not Owe Any Fees Or Obligation As A Result Of The Termination 
DataMEDS AI Moves Into Growing Peptide Market 
DataMeds AI's Pharmacy Unit Corexa Health Enters Agreement For Commercial Supply Of Six Peptides Recommended By The FDA Pharmacy Compounding Advisory Committee; Intends To Start Distributing Prescriptions In November 2026 
DataMEDS AI Launches 'Health Lives Here' Community Respiratory Program To Be Marketed To 6,500+ Independent Pharmacies In Its Corexa Health Pharmacy Network 
DataMeds AI Signs LoI To Acquire Portion Of Quality Of Life Peace Of Mind IP Portfolio For Proprietary Position Until At Least 2042 
DataMeds AI Regains Compliance With Nasdaq Equity Rule 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
DataMeds AI Enters IP License Agreement With Reboot Health AI On Oct 13, 2026; Reboot Grants DataMeds AI Exclusive License To Patents And Health AI Platform In U.S.; Reboot To Receive Portion Of DataMeds AI's Adj Gross Revenue; Co To Issue Reboot 666,667 Shares As IP License Stock Component - DataMeds AI To Collaborate With REBOOT Health AI To Integrate Its GLP Management Platform Into Its Health Lives Here Mobile App Under License Agreement
DataMeds AI Stock Rises After Humana Adds Medicaid Coverage for ChemoFx Cancer Test
Your note
Sign in to keep a note on MEDS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AJJARAPU SURENDRA K | Chief Executive Officer | Stock Award(Grant) | Jan 4, 2024 | 0 |
| DOSS HOWARD A | Chief Financial Officer | Stock Award(Grant) | Apr 13, 2020 | 12,500 |
| FELL DONALD G. | Director | Stock Award(Grant) | Aug 31, 2022 | 75,664 |
| HUFFMAN JANET | Chief Financial Officer | Stock Award(Grant) | Dec 12, 2022 | 71,551 |
| JENNINGS CHRISTINE L. | Director | Stock Award(Grant) | May 26, 2021 | 10,912 |
| NEWELL A. JEFFREY | Director | Stock Award(Grant) | Dec 29, 2022 | 79,062 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 1.11% | 13,867 | 180.96K | Jun 29, 2023 |
| Barclays Plc | 0.38% | 4,801 | 62.65K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.17% | 2,135 | 27.86K | Jun 29, 2023 |
| JP Morgan Chase & Company | 0.07% | 884 | 11.54K | Jun 29, 2023 |
| UBS Group AG | 0.07% | 900 | 11.74K | Jun 29, 2023 |
| Ronald Blue Trust, Inc. | 0.03% | 357 | 2.51K | Sep 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 1.94% | 24,189 | 101.59K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 1.23% | 15,392 | 64.65K | May 30, 2023 |
| Vanguard Extended Market Index Fund | 0.21% | 2,643 | 34.49K | Jun 29, 2023 |
| Fidelity Series Total Market Index Fund | 0.15% | 1,931 | 8.11K | May 30, 2023 |